Merus Labs International Inc (TSE:MSL) had its price target cut by equities research analysts at Paradigm Capital from C$1.75 to C$1.60 in a note issued to investors on Tuesday. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Paradigm Capital’s target price points to a potential upside of 23.08% from the company’s current price.
MSL has been the topic of several other reports. Canaccord Genuity decreased their price objective on shares of Merus Labs International from C$4.25 to C$3.50 and set a “buy” rating on the stock in a report on Tuesday, August 16th. CIBC decreased their price target on shares of Merus Labs International from C$2.90 to C$2.50 in a research note on Tuesday, August 16th. Scotiabank decreased their price target on shares of Merus Labs International from C$2.25 to C$1.75 and set a “sector perform” rating on the stock in a research note on Tuesday, August 16th. Finally, TD Securities reissued a “buy” rating and issued a C$4.00 price target on shares of Merus Labs International in a research note on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Merus Labs International currently has an average rating of “Buy” and a consensus price target of C$2.77.
Shares of Merus Labs International (TSE:MSL) opened at 1.30 on Tuesday. Merus Labs International has a 52-week low of $1.18 and a 52-week high of $2.40. The stock’s market capitalization is $152.10 million. The firm has a 50-day moving average of $1.32 and a 200 day moving average of $1.64.
Merus Labs International Company Profile
Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.
Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.